Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.18 USD
0.00 (-1.43%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.18 0.00 (0.61%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Matinas Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 3 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 28 | 25 | 24 | 19 |
Income After Depreciation & Amortization | -24 | -25 | -25 | -24 | -19 |
Non-Operating Income | 1 | 4 | 1 | 2 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -23 | -21 | -23 | -22 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -21 | -23 | -22 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -23 | -21 | -23 | -22 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -23 | -24 | -23 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -24 | -25 | -25 | -24 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 217.27 | 216.81 | 210.18 | 196.90 | 145.20 |
Diluted EPS Before Non-Recurring Items | -0.11 | -0.10 | -0.11 | -0.12 | -0.13 |
Diluted Net EPS (GAAP) | -0.11 | -0.10 | -0.11 | -0.12 | -0.13 |
Fiscal Year end for Matinas Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 1.10 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 1.10 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.89 | 6.14 | 6.16 | 6.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.89 | -6.14 | -6.16 | -5.58 |
Non-Operating Income | NA | 0.09 | 0.08 | 0.10 | 0.07 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.31 | -6.06 | -6.06 | -5.51 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.31 | -6.06 | -6.06 | -5.51 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.31 | -6.06 | -6.06 | -5.51 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 217.27 | 217.27 | 217.27 | 217.27 |
Diluted EPS Before Non-Recurring Items | NA | -0.03 | -0.03 | -0.03 | -0.03 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.03 | -0.03 | -0.03 |